检索
AI 对话
analysis
趋势分析
编组
开放平台
more
更多
排名必读论文期刊顶会热点AI 简史溯源树小脉星探人才迁徙塔尖人才国防情报追踪开源工具智慧手语
VIPCreated with Sketch.

Association Between Anti-CD20 Therapies and COVID-19 Severity Among Patients With Relapsing-Remitting and Progressive Multiple Sclerosis.

Edouard Januel,David Hajage,Pierre Labauge,Elisabeth Maillart,Jérome De Sèze,Hélène Zephir,Jean Pelletier,Laurent Guilloton,Caroline Bensa,Olivier Heinzlef,Olivier Casez,Damien Biotti,Bertrand Bourre,Sandra Vukusic,Aude Maurousset,Eric Berger,David Laplaud,Christine Lebrun-Frénay,Anne-Laure Dubessy,Pierre Branger,Eric Thouvenot,Pierre Clavelou,François Sellal,Eric Manchon,Thibault Moreau,Caroline Papeix,Florence Tubach,Céline Louapre

JAMA network open（2023）

引用 1|浏览7
暂无评分
摘要
In this cohort study, risk of severe COVID-19 was higher in patients with PMS than in those with RRMS. Use of anti-CD20 therapies was associated with an increased risk of severe COVID-19 among patients with RRMS. In patients with PMS, there was no association between anti-CD20 therapies and risk of severe COVID-19.
更多
查看译文
关键词
multiple sclerosis,relapsing-remitting
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要